Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)

The purpose of this study is to evaluate the therapeutic benefit and safety of subcutaneous (SC) Surovatamig monotherapy as consolidation therapy in patients with Chronic Lymphocytic Leukaemia (CLL)/ Small Lymphocytic Lymphoma (SLL) with unmutated IGHV (uIGHV).

Trial Details

NCT ID
NCT07509151
Phase
PHASE3
Sponsor
AstraZeneca
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Surovatamig
Locations (sample)
  • La Jolla, California, United States|32.84727,-117.2742
  • Denver, Colorado, United States|39.73915,-104.9847
  • New Haven, Connecticut, United States|41.30815,-72.92816
  • Chicago, Illinois, United States|41.85003,-87.65005
  • Kansas City, Kansas, United States|39.11417,-94.62746

Key Eligibility Criteria

  • Documented diagnosis of CLL/SLL with genomic features defined by unmutated IGHV.
  • Treatment received and response at the end of 1L (first-line) finite therapy.
  • Participants with SLL (except those in CR in Phase III part) must have measurable disease (nodal or extranodal) with at least one measurable target…
  • ECOG performance status of 0 to 2.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →